Symposium | Introduction to T-cell engagers and general mechanism of action
On March 11, 2024, the Multiple Myeloma Hub hosted a virtual symposium, “Current and future perspectives for bispecific antibodies in multiple myeloma: Learn…
On March 11, 2024, the Multiple Myeloma Hub hosted a virtual symposium, “Current and future perspectives for bispecific antibodies in multiple myeloma: Learn…
Comentamos la publicación acerca del desempeño de la nueva válvula de Edwards Sapiens S3 Ultra Resilia
Abstract. BTK inhibitors (BTKis) are established standards of care in multiple B-cell malignancies including chronic lymphocytic leukemia, mantle cell lymp
After receiving a metastatic colorectal cancer diagnosis, Jeff Williams was told he didn’t qualify for surgery. After coming to MD Anderson for a second opinion,…
Assisting Healthcare Providers with Expanded Access Requests for Investigational Oncology Products
An abstract is unavailable.
Mohamad Mohty, MD, PhD, highlights key takeaways from the 50th Annual EMBT Meeting, focusing on ongoing efforts within the GVHD treatment arena.
Felicitas Thol, MD, Hannover Medical School, Hannover, Germany, discusses the value of measurable residual disease (MRD) in guiding treatment decisions post-allogeneic stem cell transplantation (alloSCT)…
The BLA for zenocutuzumab to treat NRG1-positive non–small cell lung cancer and pancreatic cancer received priority review from the FDA.
A Roswell Park-led team uncovers beneficial effects of combining VEGFR-targeting TKIs with checkpoint inhibitors in new research.
Statin use after breast cancer diagnosis may reduce the risk of cancer-specific death but does not appear to impact the risk of recurrence, a study…